Q2 2024 Holdings
Filed 2024-08-14 | 41 holdings | $7.5B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $910.7M | 2,858,888 | 12.1% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $575.9M | 2,055,555 | 7.7% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $572.3M | 4,196,661 | 7.6% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $532.6M | 1,238,467 | 7.1% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $474.0M | 3,000,000 | 6.3% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $446.8M | 2,433,000 | 6.0% |
| Apellis Pharmaceuticals Inc.(APLS) | Common | 03753U106 | $426.2M | 11,111,111 | 5.7% |
| Biomarin Pharmaceutical Inc(BMRN) | Common | 09061G101 | $375.2M | 4,557,416 | 5.0% |
| Cerevel Therapeutics Hldng(CERE1EUR) | Common | 15678U128 | $308.3M | 7,539,547 | 4.1% |
| Spdr Series Trust - S&P Biotech(XBI) | ETF | 78464A870 | $281.4M | 3,035,000 | 3.7% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $271.8M | 27,400,000 | 3.6% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $265.7M | 6,505,000 | 3.5% |
| Arrowhead Pharmaceuticals Inc.(ARWR) | Common | 04280A100 | $231.0M | 8,888,888 | 3.1% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $220.9M | 5,666,666 | 2.9% |
| Intra-Cellular Therapies Inc(ITCIEUR) | Common | 46116X101 | $205.5M | 3,000,000 | 2.7% |
| Vera Therapeutics Inc(VERA) | Common | 92337R101 | $155.9M | 4,309,590 | 2.1% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $121.8M | 2,770,000 | 1.6% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $116.1M | 3,888,888 | 1.5% |
| Alnylam Pharmceuticals Inc.(ALNY) | Common | 02043Q107 | $97.2M | 400,000 | 1.3% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $93.8M | 11,700,000 | 1.2% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $85.3M | 2,091,666 | 1.1% |
| Merus N V | Common | N5749R100 | $80.2M | 1,355,000 | 1.1% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $79.8M | 3,888,437 | 1.1% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $77.7M | 12,570,000 | 1.0% |
| Kura Oncology Inc(KURA) | Common | 50127T109 | $72.9M | 3,541,505 | 1.0% |
| Ocular Therapeutix Inc(OCUL) | Common | 67576A100 | $55.1M | 8,060,000 | 0.7% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $45.7M | 8,759,524 | 0.6% |
| Vaxcyte Inc(PCVX) | Common | 92243G108 | $43.4M | 575,000 | 0.6% |
| Spyre Therapeutics Inc(SYRE) | Common | 00773J202 | $43.2M | 1,839,138 | 0.6% |
| Autolus Therapeutics PLC(AUTL) | Sponsored ADR | 05280R100 | $43.0M | 12,345,678 | 0.6% |
| Taysha Gene Therapies Inc(TSHA) | Common | 877619106 | $41.8M | 18,650,000 | 0.6% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $34.1M | 830,000 | 0.5% |
| Verrica Pharmaceuticals Inc | Common | 92511W108 | $29.2M | 3,999,999 | 0.4% |
| Tourmaline BIO Inc(TRML) | Common | 89157D105 | $28.6M | 2,222,222 | 0.4% |
| CG Oncology Inc(CGON) | Common | 156944100 | $22.1M | 700,000 | 0.3% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $17.0M | 4,535,000 | 0.2% |
| Bicycle Therapeutics PLC(BCYC) | Sponsored ADR | 088786108 | $14.2M | 700,000 | 0.2% |
| Aadi Biosciences Inc(WHWK) | Common | 00032Q104 | $4.2M | 2,849,402 | 0.1% |
| Dyne Therapeutics Inc.(DYN) | Common | 26818M108 | $4.1M | 115,751 | 0.1% |
| Adverum Biotechnologies Inc(AVU0) | Common | 00773U207 | $2.9M | 416,666 | 0.0% |
| Neurogene Inc(NGNE) | Common | 64135M105 | $801.6K | 22,029 | 0.0% |